Unravelling the interplay between hyperkalaemia, renin-angiotensin-aldosterone inhibitor use and clinical outcomes. Data from 9222 chronic heart failure patients of the ESC-HFA-EORP Heart Failure Long-Term Registry

Bandino S;Deidda M;Mercuro G;Cadeddu Dessalvi C;
2020-01-01

Abstract

We assessed the interplay between hyperkalaemia (HK) and renin-angiotensin-aldosterone system inhibitor (RAASi) use, dose and discontinuation, and their association with all-cause or cardiovascular death in patients with chronic heart failure (HF). We hypothesized that HK-associated increased death may be related to RAASi withdrawal.
2020
Heart failure; Hyperkalaemia; Hypokalaemia; Mineralocorticoid receptor antagonists; Prognosis; Renin-angiotensin-aldosterone system inhibitors
Files in This Item:
File Size Format  
Rossignol ejhf 2020.pdf

Solo gestori archivio

Type: versione post-print
Size 6.45 MB
Format Adobe PDF
6.45 MB Adobe PDF & nbsp; View / Open   Request a copy

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Questionnaire and social

Share on:
Impostazioni cookie